Please mention that you found the contact information on LookChem.
Tel:+1-720-2274500
Fax:
Province/state:Lancashire
City:Lancaster
Street:Patterdale Road 120-122
MaxCard:
About us
Welcome To Our Site!
In order to meet the need for pharmaceuticals on a global scale, the founding members of Hexla Molecular Laboratory Group Ltd. collaborated on mainland Chinese chemical supply chains, which led to the company’s incorporation in early 2023. To fill the gap left by businesses that were overly focused on large-scale commercial contracts, the company was founded as a typical Contract Development and Manufacturing Organization (CDMO).
We created a strategic presence in four important regulatory and industrial jurisdictions and continuously expanded our company to meet new customer needs. A facility in England for advanced SAR modelling, computational chemistry, corporate governance, and intellectual property management; a logistics department in the United States to manage regulatory issues and client relations for the Western Hemisphere Biotech Corridor; European market distribution and relations management at an EU mainland location in Germany; and, finally, development, process-chemistry optimisation, fine-chemical synthesis, API production, and quality control (QC/QA) testing in the People’s Republic of China.
In 2024, Hexla’s board approved a major structural reorganisation that allowed us to phase out western synthesis and concentrate manufacturing operations solely in China. Following this, a dual-validation bridge through professional western Heads of QC and QA was established in response to global scepticism. This logistical move significantly reduced manufacturing overhead and allowed us to offer turnaround times for complex custom APIs that were significantly faster than traditional Western CDMOs.
With the rise of private scientific foundations, research collectives, boutique clinical formulation labs, and accredited private researchers in the 2020s, Hexla launched the Private Access & Partner Programme (HPAPP) in 2025 to supply and collaborate with those who were frequently turned down by mainstream chemical suppliers due to low order volumes or strict corporate account policies.
Today, we act as a modern, hybrid chemical firm that combines high-volume chemical manufacture in China with Western quality assurance and international corporate legal monitoring to build a presence in the pharmaceutical market.
United Kingdom
